Yale Innovation Summit

Presented by Yale Office of Cooperative Research

May 9, 2018 • 8:15 AM - 5:00 PM
(Reception to follow at the Peabody Museum)

Connecting Innovators and Investors at Yale

#yaleinnovationsummit • yaleinnovationsummit.com
Thank You to Our Sponsors:

We couldn’t have done it without you!
The Blavatnik Fund is supported by a grant from the Blavatnik Family Foundation and administered by the Yale Office of Cooperative Research.

The Blavatnik Fund for Innovation at Yale supports Yale faculty in the commercialization of applied research and technology in the life sciences. A significant obstacle to the development of early-stage university discoveries is the lack of funding for the proof-of-concept and validation studies needed to demonstrate commercial potential. To overcome this barrier, the Fund provides funding and business development support to help validate nascent technologies and identify potential industry partners to advance these technologies to the marketplace.

The Fund seeks to support innovative, investigator-initiated research aimed at extending preliminary observations, with proof-of-concept and the generation of robust intellectual property as key objectives. The Fund is designed to accommodate projects of varying magnitude, as appropriate. Its primary goal is to advance technologies to the point where additional support from industry and/or technology transfer is achieved.

Supported projects may include such areas as therapeutics, diagnostics/biomarkers, medical devices, or research instruments, among others. The expected goal of completed projects will be partnerships with industry, through licenses to existing biopharmaceutical companies and startup firms (some launched from the Fund-supported technology) or via major industry-sponsored research agreements. It is expected that these alliances will lead to additional industry-sponsored research support. The Fund is structured as a sustainable, “evergreen” program, with a portion of the revenue from successfully launched technologies cycled back to support ongoing and future Fund projects.

The Fund and the progress of its supported projects are managed by the Office of Cooperative Research (OCR) under the auspices of the Office of the Provost, in consultation with an independent Investment Advisory Board comprising leaders from the various sectors of the business and investment community.

Pilot grants are eligible for up to $100,000
Development grants are eligible for up to $300,000

Projects are assessed by an external Advisory Committee composed of industry leaders

Project selection criteria:
• Research addresses an important unmet need
• Strong indication of commercial interest
• Technology is near a “value inflection point”
• Technology is patentable with freedom to operate
• Engaged, committed principal investigator

Thank you to the Blavatnik Family Foundation
Blavatnik Fellowship in Life Science Entrepreneurship

The Blavatnik Fellowship at Yale is designed to identify promising scientists and business people with a passion for biomedical entrepreneurship, to provide a hands-on experience for building their entrepreneurial skills, while simultaneously providing mentorship and professional development responsibilities. Building on the prior success of trainee programs currently running at Yale, which engage both graduate students in the life sciences as well as MBA students, this proposal seeks to leverage those efforts and position the Blavatnik Fellow as the “highest station” in the graduate fellowship ecosystem. This is a one-year fellowship with the potential of renewal for a second year.

Blavatnik Fellows enjoy a unique set of advantages:

- **Professional development** and training on a range of topics, including commercial strategy, R&D management, intellectual property, regulatory affairs, business development, and entrepreneurial financing
- **Mentorship** by distinguished business and science leaders of regional biopharma and health technology communities
- **Leadership** opportunities, including the opportunity to join and develop founding teams of new ventures

We will be seeking applications for the 2019-2020 program

November 2018
About the Yale Innovation Summit

The Yale Innovation Summit is an event highlighting entrepreneurial Yale faculty and students and the investable innovations coming out of Yale labs. The event includes a Biotech Track, aimed at those interested in commercializing ideas for drug discovery and biological therapeutics, and a Tech Track, for those interested in commercializing ideas from physical and computer sciences, engineering, software and services. In both cases, the emphasis is on developing fundable ideas and taking an entrepreneurial approach to engaging with pharmaceutical companies and venture capitalists.

Table of Contents

Program Schedule ................................................. 6

Pitch Contest Teams ............................................... 8

Speaker & Presenter Biographies ............................... 10

Sponsor Acknowledgements ................................. 30

*Program book as of May 2, 2018
Program

7:00AM  Continental Breakfast

8:15AM  OCR Opening Remarks, Jon Soderstrom

8:25AM  Keynote Speaker
Transforming Healthcare: Personal Genomes to AI Enabled Ultrasound on a Chip.
Jonathan Rothberg, 4Catalyzer
(Introduced by Michael Craig, Yale)

9:05AM  Biotech Panel 1:
China & Asia: Future Opportunities for Advancing Biotech
Moderator: Peter Farina, Canaan Partners
Panel: Haifan Lin, Yale; Jeff Chen, Ascendent Capital;
Yibing Wu, Temasek; Wei Zhao, 6 Dimensions Capital;
Stella Xu, Quan Capital

9:05AM  Tech Panel 1:
Building a Quantum Computer - Can a Yale Startup Lead the Next Generation in Computing?
Moderator: Conard Holton, Laser Focus World
Panel: Robert Schoelkopf, Yale;
Brendan Dickinson, Canaan Partners

10:10AM  Biotech Panel 2:
Trends in Biotech Investing
Moderator: Domingos Silva, Saul Ewing Arnstein & Lehr LLP
Panel: Stacey Seltzer, Aisling Capital; Jason Rhodes,
Atlas Venture; Christine Brennan, MRL Ventures Fund;
Liam Ratcliffe, New Leaf Venture Partners; Jim Reddoch,
Royalty Pharma; Karen Hong, Takeda Ventures

10:10AM  Tech Panel 2:
Blockchain & Internet Security: What Does The Future Hold?
Moderator: Tyler Kirk, Wilson Sonsini Goodrich & Rosati
Panel: Donald Fischer, TideLift; Zhong Shao, Yale; Katherine Kuzmeskas, SimplyVital Health; Maja Vujinovic, OGroup
11:00 AM   Courtyard Activities
   ePosterboards
   Lunch & Networking

12:30 PM   Biotech Pitch Contest   Zhang
Moderator: Rob Bettigole, Elm Street Ventures

12:30 PM   Tech Pitch Contest   Rm 2400
Moderator: Monica Kolinsky, Wiggin and Dana

1:35 PM   Biotech Panel 3:
Biotech Startup Ecosystems   Zhang
Moderators: Dormer Stephen, Shipman & Goodwin LLP;
Amanda Hayward, Connecticut Innovations
Panel: Maude Tessier, Merck; Amy Schulman, Polaris Partners;
Carlo Rizzuto, Versant Ventures; Tim Shannon, Canaan Partners;
Fred Cohen, Vida Ventures

1:35 PM   Tech Panel 3:
Challenges in Implementing Innovation   Rm 2400
Moderator: Bill Schnoor, Goodwin
Panel: Marc Singer, Osage University Partners; Kaushik Datta,
Mercedes-Benz USA; Adrian Horotan, Safer Made;
Yuli Ziv, Launchmetrics

2:30 PM   Coffee Break

3:00 PM   Keynote
New Paradigm of Translational Research   Zhang
Yibing Wu, Temasek
(Introduced by Haifan Lin, Yale)

3:45 PM   Keynote
Passing the Torch   Zhang
Arie Beldegrun, Leading Biotech Researcher,
Entrepreneur & Investor
(Introduced by Sean Mackay, Isoplexis)

4:25 PM   Awards Presentation   Zhang

5:00 PM   Post Event Reception   Peabody Museum
Sponsored by Wiggin and Dana
12:30 – 1:30PM
Biotech Pitch Contest (Zhang Auditorium)

Moderator: Rob Bettigole, Elm Street Ventures

Pacific Oncovirus
Lassa-VSV targets and eliminates brain cancer
Team: Anthony van den Pol

Vittix Therapeutics
Curing idiopathic pulmonary fibrosis with thyroid hormone mimetics
Team: Naftali Kaminski, Milica Vukmirovic

NASHTherapeutics
Clinical development of a compound for non-alcoholic steatohepatitis, the most common liver disease in the US
Team: Wajahat Mehal

Center Pharm
NCS1 - a new target for Wolfram syndrome
Team: Barbara Ehrlich

Domillin
Keeping the antibiotic miracle alive
Team: Mark Plummer

EvolveImmune
Novel platform technologies and targets for development of new cancer (immuno-) therapies
Team: Sidi Chen, Charles Fuchs

Paci-PHI
Evolution-proof therapy against multi-drug resistant bacterial pathogens
Team: Paul Turner, Benjamin Chan

RigActive
RIG-I agonists as next-gen immunotherapies
Team: Anna Pyle, Akiko Iwasaki
12:30 – 1:30PM
Tech Pitch Contest (Room 2400)

Moderator: Monica Kolinsky, Wiggin and Dana

**PremieBreathe**
Low-cost breathing aid for newborns
Team: Anjelica Gonzalez

**SOL**
The new face of mental health
Team: Nicholas Chedid

**HybriTech**
Hybrid technologies for cereal crops
Team: Maria Moreno

**Proteowise**
Rapid, low cost, multiplexed, bench-top proteomics
Team: Erik Gunther, Mikhail Kostylev, Stephen Strittmatter

**Expect With Me**
Revolutionizing health care by reducing costs and improving outcomes
Team: Jessica Lewis, Jeannette Ickovics

**CORISMA**
Novel cardiac device bridges critical treatment gap
Team: Jiheum Park, Pramod Bonde

**RE³MMUNE**
A genetics-free approach to producing potent T cells in a bedside manner for cancer, autoimmunity and infections
Team: Tarek Fahmy

**N⁰ Cycle**
Providing a secure supply of rare earth and specialty metals for advanced electronics
Team: Desirée Plata, Megan O’Connor
Speaker Biographies

Arie Beldegrun
Leading Biotech Researcher, Entrepreneur & Investor

Arie Beldegrun, M.D., FACS, has a distinguished career as a visionary surgeon, scientist and life sciences entrepreneur. Dr. Beldegrun is a Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine. He recently co-founded and serves as Executive Chairman of Allogene Therapeutics, a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic CAR T therapy. Dr. Beldegrun founded Kite Pharma, the cell therapy company that developed the first FDA approved autologous CAR T therapy for non-Hodgkin lymphoma. He served as Chairman, President and CEO of Kite until its acquisition by Gilead Sciences in 2017. Dr. Beldegrun has been involved with the founding and advancement of several successful companies including Cougar Biotechnology and Agensys. He is also Co-Founder and Senior Managing Director of Vida Ventures and Chairman of Two River Group and UroGen Pharma.

Rob Bettigole
Managing Partner, Elm Street Ventures

Rob is the founder and the managing partner of Elm Street Ventures. He serves on the boards of P2 Science (where he is chairman) and SeeClickFix and is Elm Street’s observer on the boards of Arvinas and Device42. Previously, Rob was a board member of AxioMx, Occam Sciences, ShareGrove, and Retail Optimization Inc., and served as an observer on the boards of Affomix, BioRelix, and Metagenomix. Before founding ESV in 2006, Rob ran an infrastructure business and helped found several start-ups. Earlier in his career, he was a venture capitalist with Rothschild Inc. and Investor AB. He began his professional career as an electrical engineer, mainly working in software.

Mr. Bettigole has a BS in Engineering and Applied Science from Yale University and an MPPM from the Yale School of Management, where he is an Executive Fellow and helps teach courses on entrepreneurship. Rob has served on the Operating Board of the Yale Entrepreneurial Institute since its inception in 2007 and is on the Investment Committee of the YEI Innovation Fund, which Elm Street Ventures also manages. He is a Licensed Professional Engineer and holds several U.S. and foreign patents.
**Jeff Chen**  
*Partner, Ascendent Capital*

Jeffrey Chen is a partner of Ascendent Capital Partners, a private equity investment management firm focused on Greater China-related investment opportunities, managing capital for global renowned institutional investors including sovereign wealth funds, endowments, pensions and foundations. Currently as head of Ascendent’s Shanghai office, he is in charge of the firm’s research and portfolio management functions.

Prior to joining Ascendent, Mr. Chen served as the Chief Strategist for Biltmore Capital Group. Prior to that, he worked for CMS Companies, an alternative investment firm based in Philadelphia, as a partner who led its structured product and fund of hedge funds team, responsible for investing 640 million USD capital in various alternative investment assets and funds. During his eleven years with CMS, his main duties included serving as the portfolio manager for three structured product funds and two funds of hedge funds. He also managed a fund of emerging market private equity funds, and one private equity fund that seeded external hedge funds, private equity funds and co-invested in private equity deals. Mr. Chen is a CFA charter holder and has earned a Master of Public and Private Management from Yale School of Management.

--

**Christine Brennan**  
*Partner, MRL Ventures Fund*

Christine has over 15 years in the life-science industry including business development, corporate strategy and venture investing. She is currently Partner at MRLV. She was previously on the board of Alimmune (NASDAQ:ALT) and an observer on the boards on a number of companies including ROX Medical, Innocrin Pharmaceuticals, Viamet Pharmaceuticals and Quartet Medicine. She is currently responsible for MRLV investments in Translate Bio and Alector.

Prior to MRLV, she was Principal at the Novartis Venture Fund from 2013-2017 and Chief Business Officer at Vitae Pharmaceuticals from 2010-2013. She also she held positions in business development and marketing at small and mid-size biopharmaceutical companies. Christine received her Ph.D. in neuroscience from Dartmouth Medical School and did post-doctoral research in developmental neurobiology from the National Institutes of Health.
Fred Cohen
Co-Founder & Senior Managing Director, Vida Ventures

Fred Cohen is a Founder and Senior Managing Director of Vida Ventures, a Biotechnology investment group. Prior to this, he was a Partner at TPG and co-founder of TPG Biotechnology, a life science focused investment effort. During his 15 years at TPG, he was responsible for co-leading the Biotechnology investment effort. The TPG Biotechnology team has invested in over 50 companies covering areas of Drug Discovery and Development, Personalized Medicine, Allied Pharmaceutical Services, Industrial Biotechnology and Medical Technology. For the last 30 years, Dr. Cohen has been at UCSF where he has had clinical responsibilities as an Internist for hospitalized patients, a consulting Endocrinologist, and as the Chief of the Division of Endocrinology and Metabolism. Prior to joining TPG, he was a Professor of Medicine, Cellular and Molecular Pharmacology, and Biochemistry and Biophysics. His research interests include structure based drug design, prion diseases, computational biology and heteropolymer chemistry. Dr. Cohen has published over 200 peer reviewed articles, participated as a co-inventor on over 10 patents and has served as an editor or editorial board member of several international scientific journals. Dr. Cohen received his B.S. degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from Oxford on a Rhodes Scholarship, his M.D. from Stanford and his postdoctoral training and postgraduate medical training in Internal Medicine and Endocrinology at UCSF. Dr. Cohen is a member of the National Academy of Medicine and the American Academy of Arts and Sciences. Dr. Cohen currently serves on the Board of Directors of several biotechnology and pharmaceutical organizations including BioCryst, CareDx, Cell Design Labs, Five Prime Therapeutics, Genomic Health, Progyny, Tandem Diabetes, Urogen and Veracyte.

Kaushik Datta
IT Innovation Hub Lead, Mercedes-Benz USA

Kaushik Datta is currently leading the IT Innovation Hub team at Mercedes-Benz USA, LLC, where he has been an employee since 2003. Prior to his current role, he managed enterprise content management platform and web applications for 65+ websites including the brand website mbusa.com, dealer facing websites and intranet websites. Kaushik has managed native mobile app development projects and rollout of apps for the enterprise and for the consumers. He has architected solutions for the Digital Dealership Experience initiatives at MBUSA. Kaushik introduced the first thin-client J2EE application and first rich internet application at MBUSA. He is the technical editor of the book Enterprise Development with Flex published by O’Reilly.
Brendan Dickinson  
*Partner, Canaan Partners*

Brendan invests in startups that are changing the world with code in the fintech, e-commerce and digital media sectors. Working at Canaan since 2010, he built Canaan’s investment thesis in insurance and is passionate about companies that re-imagine how insurance products are purchased and sold. Previously, Brendan was a senior quantitative analyst at Lehman Brothers and Barclays Capital. He holds an M.B.A. with distinction from NYU Stern School of Business, an M.S. in Computer Science from Brown University, and a B.A. in Political Science from Bowdoin College.

Peter Farina  
*Executive in Residence, Canaan Partners*

Dr. Peter Farina served as Senior Vice President of Development at Boehringer Ingelheim Pharmaceuticals, Inc. in Ridgefield, CT where he was responsible for North American pre-clinical development of drugs in the therapeutic areas of Immunology/Inflammation, virology and cardio-metabolic diseases. His career spanned 28 years and retired from the company in 2008. During his tenure as SVP, his interdisciplinary team worked on the development and successful registration of Aptivus®, an HIV protease inhibitor, Viramune XR® for HIV and Atrovent HFA® for COPD/emphysema and Jardiance® for diabetes. Prior to this position, he served as Vice President of Research at the Ridgefield Center. He has also held positions as Director of Inflammatory Diseases and Director of Biochemistry. Prior to joining BI, Dr. Farina spent 6 years in the Corporate Research Laboratories and Medical Products Division of Union Carbide Corporation in Tarrytown, NY where he worked on immunodiagnostics. Dr. Farina’s research interests have been focused on chemical and biological mechanisms impacting human disease. He has worked over his career to develop drugs to modulate inflammatory and immunological processes and was also engaged in HIV virology research which led to the discovery and successful registration of one of the first non-nucleoside reverse transcriptase inhibitors Viramune® (nevirapine).

Dr. Farina is currently an Executive in Residence at Canaan Partners, a venture capital firm located in Westport, CT. He is also the managing partner of Salient Science & Technology, LLC which advises several US and Asian biotech firms on strategic and technical matters in pharmaceutical R&D. Dr. Farina currently serves as the Co-Chair and Board Member of BioCT; the Advisory Board of the University of Connecticut School of Pharmacy (Emeritus), member of the NIH Blueprint Neurotherapeutics Network (BPN) Steering Committee; Emory University DRIVE Advisory Board, State of Connecticut Bioscience Innovation Advisory Board, and was a Founder and CEO of Developing World Cures, a nonprofit company focused on neglected diseases.

Dr. Farina has a Ph.D. in organic chemistry from SUNY Buffalo and did postdoctoral work in bioorganic chemistry at Pennsylvania State University. He also received an honorary doctorate from the University of Connecticut.
Conard Holton  
*Editor in Chief, Laser Focus World*

Conard Holton, Editor in Chief of Laser Focus World, has 30 years of science and technology editing and writing experience. He was formerly a staff member and consultant for government agencies such as the New York State Energy Research and Development Authority and the International Atomic Energy Agency, and for engineering companies such as Bechtel. He joined Laser Focus World in 1997 as senior editor, becoming editor in chief of WDM Solutions, which he founded in 1999. In 2003 he joined Vision Systems Design as editor in chief. He became editor in chief of Laser Focus World in 2011. He has a B.A. from the University of Pennsylvania, with additional studies at the Colorado School of Mines and Medill School of Journalism at Northwestern University.

Amanda L. Hayward  
*Managing Director, Venture Capital Investments, Connecticut Innovations*

Amanda Hayward, Ph.D., is a member of the Venture Team managing venture and equity investments out of CI’s life science investment funds. An experienced life science–focused executive, Amanda spent more than 17 years in venture capital, corporate strategy, business development, company formation and early-stage operations.

Amanda was most recently at Baxalta/Shire, where she was a partner on the Ventures team, making equity investments out of a $200M strategic fund focused on areas of interest to Baxalta. Prior to Baxalta, Amanda was senior vice president at Scheer and Company, Inc., where she co-founded and helped manage a number of startup companies within the context of Scheer’s venture origination practice, in addition to providing high-level strategic, business development and transaction advice to life science companies, entrepreneurs and investors.

Prior to Scheer, Amanda was the Bristol Myers Squibb Life Sciences Research Foundation postdoctoral scholar at Yale University, where her research focused on understanding molecular mechanisms contributing to cardiovascular disease.

In addition to her role at CI, Amanda is also executive chairman of Hoba Therapeutics, a venture-backed startup company based in Copenhagen, Denmark. She lives in Killingworth, Connecticut, with her two children.

Donald Fischer  
*Co-Founder and CEO, Tidelift*

Donald is co-founder and CEO of Tidelift. Previously he was a Venture Partner at General Catalyst and a member of the investment team at Greylock Partners, and an executive at Typesafe and Red Hat. He holds a BS in economics and computer science from Yale University, an M.S. in computer science from Stanford University, and an M.B.A. from Columbia Business School.
Karen Hong  
**Senior Partner, Takeda Ventures**

Prior to Takeda Ventures, Dr. Hong was Partner at ProQuest Investments, a healthcare dedicated venture fund, where she worked for fifteen years, deploying three funds and supporting all fund operations. She and her team at ProQuest guided over thirty investments to a successful exit. Dr. Hong currently serves on the Board of Directors of Palleon Pharmaceuticals, BiomX, and Emendo Biotherapeutics and is a Board Observer to Ribon Therapeutics, Encycle Therapeutics, and Arcellx. Previously, she represented ProQuest as a Director of Agile Therapeutics (Nasdaq: AGRX) and Clarus Therapeutics, and as a Board Observer to Mevion Medical Systems, Mersana Therapeutics (Nasdaq:MRSN), BioRexis Pharmaceutical Corp. (acquired by Pfizer), Gloucester Pharmaceuticals (acquired by Celgene) and LEAD Therapeutics (acquired by BioMarin), among others. She brings over twenty years of experience in life science investing and biomedical research. Prior to joining ProQuest, Dr. Hong provided technical consultation to the healthcare group at BancBoston Ventures and pursued academic research in molecular biology and chemistry. She led numerous research projects in mammalian cancer genetics and genomics in the laboratory of Dr. Eric Lander at the Whitehead Institute for Biomedical Research. Dr. Hong received a B.S. in chemistry and a B.A. in molecular biology from the University of California at Berkeley, where she graduated with honors and as a member of Phi Beta Kappa. She received a Ph.D. in biology from the Massachusetts Institute of Technology. Personal interests include skiing and biking with her husband and two children.

Adrian Horotan  
**General Partner, Safer Made**

Adrian is a general partner at Safer Made, a venture capital fund that invests in companies and technologies that bring to market products that are safer for human health and the natural world. Adrian spent the last nine years making venture investments, and the ten years prior to that working in corporate finance and banking. Before starting Safer Made, Adrian was a principal at Elm Street Ventures, an early stage venture capital fund based in New Haven, Connecticut. Adrian holds a master’s degree from the Yale School of Forestry and Environmental Studies, and an M.B.A. from INSEAD, France.

Tyler Kirk  
**Regulatory & Securities Attorney, Wilson Sonsini Goodrich & Rosati**

Tyler Kirk is a regulatory and securities attorney in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. With a broad and robust financial practice, he focuses on three key sectors of the financial industry: securities law, fintech, and payment systems. As a securities attorney, Tyler has represented private companies, banks, commodity and securities exchanges, mutual funds, exchange traded funds, insurance companies, private funds, and investment advisers.Clients in each of these categories face a daunting
Tyler Kirk
Regulatory & Securities Attorney, Wilson Sonsini Goodrich & Rosati

Tyler Kirk is a regulatory and securities attorney in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. With a broad and robust financial practice, he focuses on three key sectors of the financial industry: securities law, fintech, and payment systems. As a securities attorney, Tyler has represented private companies, banks, commodity and securities exchanges, mutual funds, exchange traded funds, insurance companies, private funds, and investment advisers. Clients in each of these categories face a daunting regulatory framework, ranging from frequent regulatory disclosures to ongoing anti-money laundering compliance. Tyler draws on his previous experience as Senior Counsel at the U.S. Securities and Exchange Commission (SEC) to guide his clients through their corporate governance obligations and to represent them before federal and state agencies. From fund formation to registered and exempt offerings to fund mergers and acquisitions, he provides thoughtful counsel to help his clients achieve their business objectives.

As a payments attorney, Tyler represents merchants, payment facilitators, money transmitters, and money services businesses, as well as credit card, prepaid card, and gift card providers. Frequently, these clients face both state and federal regulatory regimes. He listens to his clients, analyzes their business models, and crafts comprehensive strategies so his clients can confidently conduct business in full compliance with both state and federal regulators.

Tyler earned his J.D. from the University of Miami School of Law in 2012, graduating magna cum laude. He received a Master of Economics from North Carolina State University in 2007 and a B.A. in economics from George State University in 2004, graduating cum laude.

Monica Kolinsky
Associate, Wiggin and Dana

Monica is an Associate in the Corporate Department and a member of the Life Sciences Practice Group, and is based in the firm’s Stamford office.

Monica’s practice focuses primarily on life sciences and biotechnology transactional matters including licensing, corporate partnering and other technology transfer transactions. She also provides intellectual property-related support for due diligence matters, mergers & acquisitions and litigation. She is experienced in preparing and prosecuting patent applications in the life sciences area, and maintains an active patent prosecution practice. Monica works directly with a range of clients in the life sciences industry, including domestic and European public companies, and emerging biotechnology and pharmaceutical start-up companies.

Before joining the firm, Monica was Of Counsel at Grimes & Yvon LLP in New York where she prepared and prosecuted patent applications in the areas of life sciences and biotechnology and drafted and negotiated agreements related to intellectual property and research materials. She was previously a Licensing Officer for Medical Research Council Technology (now known as LifeArc) in London, England and an Associate and Technology Specialist at WilmerHale in New York. Monica was short-listed as a 2017 U.S. Rising Transactional Star by LMG Life Sciences.

Monica holds a Ph.D. in Pharmacology from Cornell University, Weill Graduate School of Medical Sciences and she earned her J.D., cum laude, from New York Law School. She earned her B.S., cum laude, from Moravian College with a major in Biology and a minor in Chemistry and was an undergraduate Carolina Summer Research Fellow in the Pharmacology department at the University of North Carolina – Chapel Hill.
Haifan Lin

Eugene Higgins Professor of Cell Biology and Founding Director of Yale Stem Cell Center, Professor of Genetics, of Obstetrics, Gynecology, and Reproductive Sciences, and of Dermatology; Founding Dean, School of Life Science and Technology, ShanghaiTech University

Dr. Lin studies the self-renewing mechanism of stem cells, using Drosophila germline stem cells, mouse germline, embryonic, and neural stem cells, as well as Hydra and planarian stem cells as models. He also works on stem cell-related cancers and germline development. Dr. Lin received his BS degree from Fudan University, PhD degree from Cornell University, and postdoctoral training at the Carnegie Institution for Science. He joined the faculty of Duke University Medical School in 1994, where he rose to Full Professor. He founded and directed the Duke Stem Cell Research Program, and moved to Yale in 2006 to establish Yale Stem Cell Center. He has also been building School of Life Science and Technology at ShanghaiTech University (2014-). Dr. Lin has made key contributions to the demonstration of stem cell asymmetric division and the proof of the stem cell niche theory. He discovered the Argonuate/Piwi gene family and their essential function in stem cell self-renewal and germline development. He is also a discoverer of PIWI-interacting RNAs (piRNAs), a discovery hailed by Science as one of the 10 Breakthroughs in 2006. Recently, he demonstrated the crucial roles of the Piwi-piRNA pathway in epigenetic programming and in post-transcriptional regulation of mRNA and IncRNA.

Dr. Lin has been serving various leadership roles in the International Society for Stem Cell Research, the greater scientific community, and beyond. He received over 30 awards in his career. He is a member of the US National Academy of Sciences, a member of the American Academy of Arts and Sciences, and a fellow of the American Association for Advancement of Science.
Liam Ratcliffe  
**Managing Director, New Leaf Venture Partners**  

Liam Ratcliffe is the Managing Director at New Leaf Venture Partners, and concentrates on biopharmaceutical investing. Liam joined New Leaf in September 2008. Liam previously served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Mid West region (based in Ann Arbor, MI), and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories. As Head of Neurosciences, Liam was responsible for the development of several successful late-stage projects and marketed products, including Lyrica, Chantix and Geodon. In previous roles, he gained extensive experience in early drug development and translational research across multiple therapeutic areas, including inflammation, pain, cardiovascular disease, infectious diseases and genito-urinary medicine.

Liam began his career in the pharmaceutical industry in a medical marketing role at Roche in South Africa. He received his M.D. degree and Ph.D. degree in immunology from the University of Cape Town and his M.B.A. degree from the University of Michigan. Liam completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa.

Liam also serves on various industry panels, including the Leadership Counsel of the University of Michigan Life Sciences Institute, the Advisory Council of the Keck Graduate Institute, the Life Sciences Advisory Panel of Frankel Consulting and the Pfizer External Advisory Panel for Ophthalmology, the AstraZeneca External Advisory Panel for Research & Development Strategy and Anti-Infectives.

---

Tyler Kirk  
**Regulatory & Securities Attorney, Wilson Sonsini Goodrich & Rosati**

Tyler Kirk is a regulatory and securities attorney in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. With a broad and robust financial practice, he focuses on three key sectors of the financial industry: securities law, fintech, and payment systems. As a securities attorney, Tyler has represented private companies, banks, commodity and securities exchanges, mutual funds, exchange traded funds, insurance companies, private funds, and investment advisers. Clients in each of these categories face a daunting regulatory framework, ranging from frequent regulatory disclosures to ongoing anti-money laundering compliance. Tyler draws on his previous experience as Senior Counsel at the U.S. Securities and Exchange Commission (SEC) to guide his clients through their corporate governance obligations and to represent them before federal and state agencies. From fund formation to registered and exempt offerings to fund mergers and acquisitions, he provides thoughtful counsel to help his clients achieve their business objectives.

As a payments attorney, Tyler represents merchants, payment facilitators, money transmitters, and money services businesses, as well as credit card, prepaid card, and gift card providers. Frequently, these clients face both state and federal regulatory regimes. He listens to his clients, analyzes their business models, and crafts comprehensive strategies so his clients can confidently conduct business in full compliance with both state and federal regulators.

Tyler earned his J.D. from the University of Miami School of Law in 2012, graduating magna cum laude. He received a Master of Economics from North Carolina State University in 2007 and a B.A. in economics from George State University in 2004, graduating cum laude.

---

Sean Mackay  
**Co-Founder, CEO & Director, Isoplexis**

Sean Mackay is the Co-Founder, Chief Executive Officer and Director of IsoPlexis, a venture capital-funded life sciences company dedicated to accelerating the fight against cancer, autoimmune disease and more through its single-cell precision engineering platform. Sean is an experienced entrepreneur, specializing in the convergence of life sciences and health care delivery. In partnership with co-founders at Yale and Caltech, Sean led IsoPlexis through foundational licensing and capital raising, while building a scientific and engineering team to develop applications and product. At IsoPlexis, Sean has enabled the development of multiple academic and biopharmaceutical collaborations in immuno-oncology patient response detection to advance single-cell precision medicine solutions in this fast-moving field. Previously, Sean advanced business development at Kleiner Perkins-backed and incubated Lifesquare, which connected patients, payers and providers through sharing essential health care information. Through work at Lazard and several early-stage ventures, he developed deep expertise in structuring and financing life sciences companies. While at Lazard, Sean advised multiple biotechnology and medical technology companies on how to manage times of strategic change. Sean graduated with a B.S. in Economics from the University of Pennsylvania’s Wharton School and an M.B.A. from the Yale School of Management.
Jim Reddoch

Executive Vice President for Research and Investments,
Royalty Pharma

Jim Reddoch, Ph.D., is Executive Vice President for Research and Investments at Royalty Pharma. He leads a team of professionals who focus on sourcing and analyzing new opportunities and partnerships. In his 10-year tenure at Royalty Pharma, the firm has invested close to $12 billion in over 20 transactions in both approved and unapproved assets. In the past five years, Royalty Pharma has pioneered the creation of synthetic royalties to fund individual clinical-stage products.

Prior to joining Royalty Pharma in 2008, Jim was Senior Vice President and Head of Healthcare Research and FBR Capital Markets, where he published on biopharmaceutical stocks and led a team of equity research analysts in five healthcare verticals. His prior experience includes serving as a biotechnology analyst at Bank of America and CIBC World Markets. Jim has a Ph.D. in Biochemistry and Molecular Genetics from University of Alabama at Birmingham, and later worked as a postdoctoral fellow at Yale University in the lab of Peter Glazer. He moonlighted at Yale's Office of Cooperative Research. He has a B.A. from Furman University.

He is on the board of Avillion, a London-based drug development company also funded by Clarus and Abingworth. Jim serves on Memorial Sloan Kettering Cancer Center's external review committee for its Technology Development Fund (TDF).

Jason Rhodes

Partner, Atlas Venture

Jason Rhodes is a partner at Atlas Venture and focuses on the creation, development, and business strategy of novel therapeutics companies. He sits on the boards of Atlas portfolio companies Replimune, Bicycle Therapeutics, and several seed-stage companies. Prior to joining Atlas, Jason was president and CFO of Epizyme (NASDAQ: EPZM), which he joined when it was a private, research-stage company and helped lead through a series of successful partnerships and an IPO in 2013. Prior to that Jason was vice president of business development at Alnylam (NASDAQ: ALNY), and he was a founder and partner with Fidelity Biosciences before that. Jason received his B.A. from Yale University and his M.B.A. from the Wharton School of the University of Pennsylvania. He is a member of the advisory board of the BIDMC Institute for RNA Medicine, the investment advisory board of the Blavatnik fund at Yale, the industry advisory board of the Models to Medicine (M2M) Center at UMass Amherst, and the Berklee College of Music Presidential Advisory Council.
Jonathan Rothberg  
*Chief Strategy Officer, 4Catalyzer & Inventor of High-Speed DNA Sequencing*

4Catalyzer, founded by Jonathan Rothberg, is a startup accelerator based in Guilford, Connecticut, that is dedicated to maximizing societal impact by developing new types of sensors and pairing them with deep learning to get a new window into biology and medicine. Dr. Rothberg was awarded the National Medal of Technology by President Obama for inventing massively parallel DNA sequencing (NextGen), bringing it to market first, sequencing the first personal genome (Jim Watson), inventing semiconductor sequencing, sequencing first on a semiconductor chip (Gordon Moore Genome), leading the team that sequenced Neanderthal Genome (with Svante Paabo), and elucidating the extent of individual human variation. The New England Journal described Dr. Rothberg's sequencing innovation as enabling “The New Age of Molecular Diagnostics...” and he was recognized by Science magazine as one of the top 10 breakthroughs for 2007 & 2008. He also developed Glembatumumab Vedotin, a promising drug for Breast Cancer. As the founder of Butterfly Network, Dr. Rothberg invented the first ultrasound-on-a-chip and in 2017 received clearance from the FDA for the World's first whole-body scanner, reducing the cost of medical imaging 50-fold and democratizing ultrasound.

Dr. Rothberg was born in 1963 in New Haven, Connecticut. He earned a B.S. in chemical engineering from Carnegie Mellon University and Ph.D. in biology from Yale University. He's the winner of The Wall Street Journal's Gold Medal for Innovation, and Nature Method's first Method of the year award. Dr. Rothberg's scientific work has been featured on the covers of Cell, Science, and Nature. He is the first person ever to be named four times as a World Economic Forum Technology Pioneer, is a member of the National Academy of Engineering, The Connecticut Academy of Science and Engineering, and was named a Life Trustees of Carnegie Mellon University, and is an Adjunct Professor of Genetics at Yale.

Carlo Rizzuto  
*Partner, Versant Ventures*

Carlo Rizzuto is a Partner with Versant Ventures and focuses on biotech investing and company building.

Carlo joined Versant from Novartis Pharmaceuticals where he led global product development teams in the advancement of innovative pipeline products. He previously held the position of Associate Principal with McKinsey & Company advising US and European clients in the pharmaceutical, payor and provider sectors. Prior to joining McKinsey, Carlo helped found engeneOS, a Boston-based biotech startup.

Carlo received a Ph.D. in Virology from Harvard University and a B.A. in Biology from the University of Virginia.
Robert Schoelkopf

Sterling Professor of Applied Physics and Physics, Yale Co-Founder & CEO, Quantum Circuits, Inc.

Robert Schoelkopf, the Sterling Professor of Applied Physics and Physics at Yale University, is a Co-Founder of Quantum Circuits, Inc. and its Chief Executive Officer. He is also the Founding Director of the Yale Quantum Institute. His research focuses on the development of superconducting devices for quantum information processing, which are leading to revolutionary advances in computing. He and his collaborators have produced many firsts in the field of solid-state quantum computing, including the development of a “quantum bus” for information, and the first demonstrations of quantum algorithms and quantum error correction with integrated circuits. A graduate of Princeton University, Schoelkopf earned his Ph.D. at the California Institute of Technology. From 1986 to 1988 he was an electrical/cryogenic engineer in the Laboratory for High-Energy Astrophysics at NASA’s Goddard Space Flight Center, where he developed low-temperature radiation detectors and cryogenic instrumentation for future space missions. Schoelkopf, who came to Yale as a postdoctoral researcher in 1995, joined the faculty in 1998, becoming a full professor in 2003. Professor Schoelkopf’s work has been recognized with several honors and awards, including the Joseph F. Keithley Award of the American Physical Society (2009), the John Stewart Bell Prize (2013, with Michel Devoret) for fundamental and pioneering experimental advances in superconducting qubits, the Fritz London Memorial Prize for Low Temperature Physics (2014, with Devoret and John Martinis), the Max Planck Forschungspreis (2014), and the CT Medal of Science (2017). In 2015, Professor Schoelkopf was elected to the National Academy of Science.

Bill Schnoor

Partner, Goodwin

Bill Schnoor is a partner in and former co-chair of the firm’s Technology Companies + Life Sciences Group. He is one of the leaders of Goodwin’s interdisciplinary practice focusing on investments in alternative energy and clean technologies, concentrates in the areas of business and securities law, private equity and acquisitions. He joined Goodwin in 2005, after a 21-year career with Testa, Hurwitz & Thibeault, LLP.

Mr. Schnoor represents start-ups and other private and public companies in a wide range of industries. He has worked with numerous companies from their initial financing through initial public offerings or acquisitions, and has advised numerous public companies and their boards of directors. Mr. Schnoor works with companies across a broad range of industries, including alternative energy and other clean technologies; ecommerce and other internet-based businesses; enterprise software; life sciences; and healthcare information technology.

A significant portion of Mr. Schnoor’s practice has involved cross-border financings and acquisitions. He has represented numerous investment banks in connection with underwritten offerings and their activities as financial advisors to companies engaged in mergers and acquisitions. Mr. Schnoor has also represented numerous private equity clients in connection with their own fund-raising and internal organizational issues as well as in making portfolio investments and in connection with matters affecting their portfolio companies.

Prior to joining Goodwin, Mr. Schnoor was a partner in the Business Practice Group at Testa, Hurwitz Thibeault in Boston.

Mr. Schnoor has been selected for inclusion in Chambers USA: America’s Leading Lawyers for Business, U.S. News-Best Lawyers and The Legal 500 U.S.

Mr. Schnoor speaks frequently on financing, entrepreneurship and public offerings. He has presented to the Massachusetts Institute of Technology Sloan School New Enterprise course on “Legal Issues for Start-Ups,” and has appeared as a guest at the Harvard Business School course on Entrepreneurial Management on legal topics. Mr. Schnoor is also on the Advisory Board to the Yale Entrepreneurial Institute and has participated as a judge in the Yale Y50k business plan competition.

Mr. Schnoor received his B.A. from Yale University, summa cum laude, and his J.D. from Yale Law School.
Robert Schoelkopf
Sterling Professor of Applied Physics and Physics, Yale
Co-Founder & CEO, Quantum Circuits, Inc.

Robert Schoelkopf, the Sterling Professor of Applied Physics and Physics at Yale University, is a Co-Founder of Quantum Circuits, Inc. and its Chief Executive Officer. He is also the Founding Director of the Yale Quantum Institute. His research focuses on the development of superconducting devices for quantum information processing, which are leading to revolutionary advances in computing. He and his collaborators have produced many firsts in the field of solid-state quantum computing, including the development of a “quantum bus” for information, and the first demonstrations of quantum algorithms and quantum error correction with integrated circuits.

A graduate of Princeton University, Schoelkopf earned his Ph.D. at the California Institute of Technology. From 1986 to 1988 he was an electrical/cryogenic engineer in the Laboratory for High-Energy Astrophysics at NASA’s Goddard Space Flight Center, where he developed low-temperature radiation detectors and cryogenic instrumentation for future space missions.


Professor Schoelkopf’s work has been recognized with several honors and awards, including the Joseph F. Keithley Award of the American Physical Society (2009), the John Stewart Bell Prize (2013, with Michel Devoret) for fundamental and pioneering experimental advances in superconducting qubits, the Fritz London Memorial Prize for Low Temperature Physics (2014, with Devoret and John Martinis), the Max Planck Forschungspreis (2014), and the CT Medal of Science (2017). In 2015, Professor Schoelkopf was elected to the National Academy of Science.

Amy Schulman
Partner, Polaris Partners

Amy W. Schulman is an accomplished business leader, widely recognized for growing and stabilizing global businesses, commitment to people, strategic judgment, and efforts to advance women and promote inclusive workplace cultures.

Ms. Schulman joined Harvard Business School’s Faculty as a Senior Lecturer in July 2014. In 2014, Ms. Schulman also joined Polaris Partner’s Boston office, simultaneously assuming the role of Chief Executive Officer (CEO) of Arsia Therapeutics, a Polaris-backed company which was acquired by Eagle Pharmaceuticals in 2016. In 2015, Ms. Schulman cofounded Lyndra, where she is CEO. She became CEO and Executive Chair of Olivo Laboratories in 2017, which sold its cosmetic business to Shiseido in 2018, and serves as Executive Chair of SQZ Biotech and Suono Bio.

Previously, Ms. Schulman led Pfizer Inc.’s $4 billion Consumer Healthcare business, which operates in 90 countries and includes well-known brands such as Advil, Centrum, and Chapstick. She also served as Executive Vice President and General Counsel of Pfizer Inc. Ms. Schulman originally joined Pfizer in 2008 as General Counsel and saw the company through its $68 billion acquisition of Wyeth, the largest pharmaceutical acquisition in history. In 2009, she spearheaded an innovative approach to engaging outside counsel and became recognized as a leading voice for transforming the billable-hour model and for redefining the value of legal services.

Before joining Pfizer, Ms. Schulman was a partner at DLA Piper, where she was a member of the Board and Executive Policy Committees, and built and led the international law firm’s
mass tort and class action practice handling some of the most complex legal, scientific and regulatory challenges facing the world’s largest and most reputable companies, including Kraft, Altria, Cisco, GE Healthcare, and Pfizer. She began her career in litigation with Cleary Gottlieb Steen & Hamilton.

Ms. Schulman’s accomplishments have earned her accolades from leading publications and organizations. The American Bar Association honored her with the Margaret Brent Women Lawyers of Achievement award in 2012. In 2013 Fortune magazine named her one of the “50 Most Powerful Women in Business.” That same year, The American Lawyer named her one of the “Top 50 Innovators,” and The National Law Journal named her one of “The 100 Most Influential Lawyers in America.” She was also included in Fierce Biotech’s 2014 “Top 15 Women in Biotech” and Scientific American’s 2015 “Worldview 100 List.” In 2017, she was chosen to speak at Tedmed and was the recipient of a Boston Xconomy Award.

A Phi Beta Kappa graduate of Wesleyan University, Ms. Schulman earned her J.D. from Yale Law School in 1989. She serves on the Board of Directors of Alnylam Pharmaceuticals, Arsanis, Blue Buffalo, Ironwood Pharmaceuticals, and the Whitehead Institute.

Stacey Seltzer
Partner, Aisling Capital

Ms. Seltzer joined Aisling in 2008 and currently serves as a Partner. Previously, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving as the U.S. Schering-Plough Brand Lead for Zetia. While in business development, Ms. Seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions, ranging from in-licensing deals to broad development and commercialization alliances. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company.

Ms. Seltzer serves as a director of Aimmune Therapeutics and Promentis Pharmaceuticals, and as a Board observer of Prolacta Bioscience. Previously, she served as a director of Miramar Labs (acquired by Sientra) and as a Board observer for Agile Therapeutics, Durata Therapeutics (acquired by Actavis) and ZELTIQ Aesthetics (acquired by Allergan). She also acted as the Aisling representative for its investment in PreCision Dermatology (acquired by Valeant) and was closely involved in Aisling’s investments in Dermira and PowerVision.

Ms. Seltzer received her M.B.A. from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar. She received her M.S. and B.S. from Yale University, awarded *cum laude* in Molecular Biophysics and Biochemistry.
Tim Shannon  
*General Partner, Canaan Partners*

For more than 25 years, Tim Shannon has been an entrepreneur, executive, researcher, professor, and practicing physician in pulmonary and critical care medicine. A Canaan investor since 2009, we rely on Tim’s operating experience to help companies grow from their earliest stages to funded companies creating value through partnerships, M&A and IPOs. Most recently, Tim was startup CEO and currently serves as the Chairman of Arvinas, named by Fierce Biotech as a Fierce 15 company of 2015.

Tim was one of the early institutional investors and remains on the board of CytomX Therapeutics, which completed a $92 million initial public offering in October 2015 (NASDAQ: CTMX). He was a co-lead Series A investor in Civitas Therapeutics, which was acquired by Acorda Therapeutics in October 2014 for $525 million, and a lead Series A investor in Novira Therapeutics, Inc. which was acquired by Johnson & Johnson in December 2015. In addition, he serves on the boards of IDEAYA Biosciences, NextCure, Spyryx Biosciences, Vivace Therapeutics and VaxInnate Corporation.

Prior to Canaan, Tim was president and chief executive officer of CuraGen, a publically traded biopharmaceutical company focused on oncology, after serving as executive vice president of R&D and chief medical officer. Earlier he was the senior vice president and head of global clinical development for Bayer’s Pharmaceutical Business Group. Tim began his career as assistant professor of the pulmonary and critical care division at Yale University School of Medicine.

Tim received his post graduate medical training at the Beth Israel Hospital of Harvard Medical School and at Boston University, earned his medical degree from the University of Connecticut, and has a B.A. in chemistry from Amherst College.

Zhong Shao  
*Thomas L. Kempner Professor of Computer Science, Yale*

Zhong Shao is Thomas L. Kempner Professor of Computer Science and Department Chair in the Computer Science Department at Yale University. He currently leads the FLINT group which aims to develop new languages and tools for building large-scale certified system software.

He earned his PhD in Computer Science from Princeton University in 1994. During the last 15 years, Shao and his FLINT group at Yale have led and pioneered work on language-based approaches to safety and security, certified OS kernels and hypervisors, compositional resource bound analysis, certified compilation, and formal methods. He was also a PI on the DARPA OASIS Proof-Carrying Code Project (1999-2004), the DARPA CRASH CertiKOS Project (2010-2014), the DARPA HACMS CARS Project (2012-2017), and NSF’s new Expeditions-in-Computing project on the Science of Deep Specification (2015-2020). Shao’s work on CertiKOS is widely considered as a breakthrough toward building hacker-resistant operating systems that are provably free from cyber vulnerabilities. Shao is co-founder of a new blockchain startup, CertiK, which aims to develop a formal verification platform for next-generation smart contracts and blockchain ecosystems. He also serves on the Technical Advisory Board of Symbiont, another blockchain startup on building safe and powerful financial applications using smart contracts.
**Domingos J. Silva**  
*Associate, Saul Ewing Arnstein & Lehr LLP*

Domingos J. Silva is a patent attorney in the Philadelphia office of Saul Ewing Arnstein & Lehr LLP. Domingos’s practice spans patent prosecution, opinion work, and client counseling, and his clients include universities, start-ups, companies of various sizes, and venture funds. He has extensive experience in the chemical, materials science, pharmaceutical, diagnostics, biotechnology, and biochemistry areas.

Domingos has a long professional history in the science field. After obtaining a Ph.D. in Organic Chemistry from Princeton and pursuing his postdoctorate fellowship work at MIT, Domingos embarked on a career as a research scientist for Incara Research Labs, and later as medicinal chemistry manager in the oncology and antibacterial programs for GlaxoSmithKline. As a medicinal chemist, Domingos co-authored 16 peer-reviewed publications, and was named as inventor in 17 patent applications. At GlaxoSmithKline, he was a member of the development team for a novel kinase inhibitor, which was eventually approved by the FDA as an oral antitumor agent.

Domingos became a registered patent agent in 2009. Prior to joining Saul Ewing Arnstein & Lehr, Domingos worked for a boutique intellectual property firm and a large Philadelphia law firm. He is a member of American Chemical Society, AUTM, AIPLA, and Life Sciences PA. Domingos is admitted to practice in Pennsylvania and New Jersey, and before the U.S. Patent and Trademark Office.

**Marc Singer**  
*Managing Partner and Co-Founder, Osage University Partners*

Marc Singer is a Managing Partner and Co-Founder of Osage University Partners (“OUP”), which he joined in 2008. Marc manages all of OUP’s technology investing activities, including software, hardware, semiconductors, advanced materials, and more. OUP partners with high quality university and research institutions to serve as their coinvestment vehicle in start-ups that are licensing their technology. Osage works with its partner institutions to build a broad venture capital portfolio across a range of advanced technologies, including software, hardware, advanced materials, life sciences, and more. Osage and its partner institutions share in the profit of the fund, helping to align each institution’s incentives with those of its companies and their investors. OUP has partnered with over 80 research institutions, including Caltech, Columbia, Duke, Florida, Harvard, Michigan, Penn, UC Berkeley, and many others. OUP has over $300 million in capital under management and has invested in over 70 university start-ups.

Marc has spent more than twenty years in venture capital. He previously served as a General Partner and Co-Founder of BEV Capital, an early stage venture capital firm he co-founded in 1997. Over ten years Marc helped BEV raise and invest over $200M in over 40 companies and co-invest with over 100 other venture capital firms. Marc managed or co-managed eighteen of BEV’s investments and successfully managed multiple companies from start-up through IPO or trade sale. Prior to co-founding BEV in 1997, Marc worked at Consumer Venture Partners, another VC firm he joined in 1993. Marc earned his B.S. from The Wharton School of the University of Pennsylvania.
Dormer Stephen  
*Partner, Shipman & Goodwin LLP*

Dormer Stephen is Co-Chair of the Shipman & Goodwin's Business and Finance Practice Group. Dormer handles venture capital and private equity and debt transactions, mergers and acquisitions and general corporate matters. His practice involves the representation of Fortune 500 companies, private equity funds, emerging growth companies and investment banks in structuring, negotiating and documenting seed through later stage equity and debt investments, mezzanine financings, syndicated credit facilities, mergers and acquisitions, buyouts, rollup strategies, joint ventures, intellectual property transactions, work-outs and financial restructurings and general corporate matters. Constituent companies are in a broad range of industries including financial services, insurance, life sciences, media, software and telecommunications. He also represents public and private clients in an “outside general counsel” capacity. Roles include counseling on strategic initiatives (such as joint ventures, joint development projects and intellectual property licensing and collaboration), commercial contract matters (such as distribution and supply agreements, license agreements and employment agreements) and other general corporate matters (such as employment and severance matters, equity incentive plans, corporate governance, real estate matters and insurance matters).

Maude Tessier  
*Executive Director, Business Development & Licensing, Merck*

Maude brings over 12 years of business development and licensing experience in pharma, biotech and academia. Maude is currently Executive Director, Business Development & Licensing in the Boston Innovation Hub at Merck & Co. The Boston Hub is responsible for finding, evaluating and transacting on pre-POC opportunities in the New England area and parts of Canada. Maude is a Co-Chair of the Business Development & Finance Working Group at MassBio. Prior to joining Merck, Maude was Assistant Director, Business Development and Strategic Initiatives in the Technology and Innovation Development Office (TIDO) at Boston Children’s Hospital. In this role, she initiated, developed and realized discovery alliances between Boston Children’s and industry partners, as well as lead TIDO’s marketing team efforts including external and internal communications, outreach events and strategic marketing initiatives. Maude began her career at Xanthus Pharmaceuticals, a small venture-backed oncology biotech company in Cambridge, MA, where she had key roles in Business Development, and Program Management of a Phase 3 asset and its eventual FDA approval. Maude earned her Ph.D. from the Department of Medical Biophysics at the University of Toronto. Her graduate research was focused on identifying and characterizing a novel serine/threonine protein kinase involved in cancer.
Maja Vujinovic
CEO, OGroup

Maja Vujinovic started her career as an entrepreneur in mobile payments in Sub Saharan Africa. Working across 5 continents Maja built government and enterprise infrastructure across industries such as mobile tech, global payments, energy and healthcare. She took interest in bitcoin in 2011.

In her past role, as a Chief Innovation Officer of Emerging Tech at General Electric, Digital, she spearheaded the full framework for blockchain. She ran pilots across treasury, aviation, energy, provenance and additive manufacturing. Maja was a catalyst for an electronic wallet for machines in GE’s brilliant factory project. She disrupted current business models through concepts of tokenization and helped design the Future of Work group (looking at the effect of emerging technology and digital economy on employees and workforce).

Maja currently runs OGroup. OGroup is an investment firm focused on token economics and blockchain for enterprise. She sits on the board of CoinDesk.

Yibing Wu
Joint Head, Portfolio Strategy and Risk Group, Temasek

Mr. Wu joined Temasek in October 2013 and is currently Joint Head, Portfolio Strategy & Risk Group and Joint Head, China. Mr. Wu was previously President of CITIC Private Equity Funds Management, a position he held since December 2009. He concurrently served as Chairman and CEO of Goldstone Investment Co. Ltd., the direct investment arm of CITIC Securities.

Mr. Wu began his career with McKinsey, rising to become Senior Partner and Head of Asia Pacific M&A Practice. He was also General Manager of McKinsey Beijing, where he was responsible for providing M&A, corporate restructuring and IPO advisory for large Chinese enterprises. He had advised a number of leading Asian companies in their international expansion effort. He subsequently joined the Lenovo Group, and led the acquisition and integration of the IBM PC business, serving as Chief Strategy Officer, Chief Integration Officer, Chief Transformation Officer/ Chief Information Officer of Lenovo Group.

Mr. Wu was later appointed to Lenovo parent Legend Holdings, as Executive Vice President responsible for the overall business operations and overseeing its direct investment business.

Mr. Wu serves on the board of China Social Entrepreneur Foundation.

Mr. Wu holds a Ph.D. in Biochemistry from Harvard University and a BSc. in Molecular Biology from University of Science and Technology of China.
Stella Xu  
*Managing Director, Quan Capital*

Dr. Stella Xu is Managing Director of Quan Capital, a life sciences venture fund with offices in China & US, and deep expertise in cross-border value creation and global investments. Prior to Quan, Dr. Xu was a core member of the global management team for Roche’s Immunology, Inflammation & Infectious Diseases areas, and VP/Site Head of Roche Innovation Center Shanghai. From 2012-2017, she led the integrated research & early development site of ~200 scientists, successfully delivered a world-class innovative pipeline from Discovery to global Clinical Development in 3 years, and pioneered novel development strategies in China. Prior to her R&D leadership role, Dr. Xu had extensive global business development and licensing experiences across deal types and disease areas. After establishing the Roche Partnering office in Shanghai in 2008, she managed business development activities in APAC (ex-Japan). She also led global due diligence transaction activities and managed key alliances from research collaboration to marketed products in Roche Partnering US for years. Dr. Xu joined Roche from McKinsey US where she led management consulting engagements in diverse healthcare sectors and functional areas from R&D to commercialization. Earlier in her career, Dr. Xu worked in biotech R&D in oncology & inflammation.

Dr. Xu received her Ph.D. in Immunology from Northwestern University, and B.S. in Biophysics from Peking University.

Dr. Xu currently serves on the Board of ARMO BioSciences, Centrexion Therapeutics and Tempest Therapeutics.

Wei Zhao  
*Vice President, 6 Dimensions Capital*

Wei Zhao joined WuXi Healthcare Ventures (now 6 Dimensions Capital) in 2016. Prior to that, Wei was a Senior Life Sciences Specialist at L.E.K. Consulting, and a postdoctoral fellow at Mass. Eye and Ear Infirmary and Harvard Medical School. Wei obtained his Ph.D. in Neuroscience from Northwestern University, and B.S. from Tsinghua University.
Yuli Ziv  
**CEO, Influencer Marketing Division & Co-Managing Director, USA at Launchmetrics**

Yuli Ziv is an entrepreneur who pioneered the influencer marketing industry. In 2008 she founded Style Coalition, one of the very first influencer marketing platforms. In 2017 Style Coalition was acquired by Launchmetrics, one of the largest global technology and data analytics provider for the Fashion, Luxury & Cosmetic industries. Yuli currently leads company’s Influencer Marketing division and co-manages the USA business unit.

Yuli is a noted speaker on the topic of social media, who keynoted and moderated panels at numerous conferences including DLD, CE Week, MAGIC & Luxury Retail Summit. Yuli has been featured numerous times in major publications including: The New York Times, Financial Times, Wall Street Journal, Forbes, Entrepreneur and Business Week. Prior to founding her own ventures, Yuli developed & led online strategies at various online advertising networks and digital agencies.


---

**Thank You to Our Speakers and Panelists**
Sponsors

Thank you to our sponsors for your generous support - without it, this event would not be possible.

Lead Sponsors

Shipman & Goodwin LLP is a full service law firm with more than 175 attorneys in offices throughout Connecticut, New York and in Washington, DC. Our clients include public and private companies, institutions, government entities, non-profit organizations and individuals. Shipman & Goodwin has long enjoyed helping start-up and emerging growth companies to succeed. Our counsel includes matters related to formation, governance, intellectual property, technology and trademark protection and commercialization, equity and debt financings, research and development and collaboration arrangements, strategic alliances and joint ventures and spin-outs, acquisitions and dispositions, government and philanthropic grant arrangements, executive compensation and equity incentive plans and regulatory counseling and compliance. Our clients compete in various industries, including life sciences, software and IT, energy and alternative energy, education, nanotechnology, engineered materials, semiconductors, telecommunications, e-commerce, media and health care.

Connecticut Innovations (CI) is Connecticut’s strategic venture capital arm and is the leading source of financing and ongoing support for innovative, growing companies. CI provides venture capital and strategic support for early-stage technology companies; financial support for innovation and collaboration; and connections to its well-established network of partners and professionals. We can make introduction to our vast network of small and big businesses, talent, university researchers, service providers, suppliers and more. Our business advisers are mentors who specialize in your sector and have the skills you need. We see venture capital the way you see your business - Like no one else! For more information, please visit www.ctinnovations.com.
Goodwin is a leading Am Law 50 and Global 50 law firm, with offices across the United States and in Europe and Asia. Excelling at complex transactional work and high-stakes litigation, the firm combines in-depth legal knowledge with practical business experience to help clients maximize opportunities and manage risk. With more than 1,000 lawyers, Goodwin offers innovative counsel and delivers results through a client-centric and collaborative approach. The firm focuses on matters involving financial institutions, intellectual property, private equity, real estate capital markets, securities litigation/white collar defense, and technology/life sciences. Information may be found at www.goodwinlaw.com. Follow us on Twitter @goodwinlaw.

Merck has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide. From Merck’s development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines. In 2017, over 60% of our human health sales were attributable to alliance partnerships and patents. With 100 business development transactions since 2016, our team has experience working on collaborations from discovery to clinical-stage programs. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life. Learn more at merck.com/licensing.
Wilson Sonsini Goodrich & Rosati’s patents and innovation practice helps clients leverage their intellectual property, defend against claims of others, and establish a competitive position for the future in fields such as therapeutics, personalized medicine, research tools, and clean technologies. Our team helps growing companies achieve important milestones by securing, developing, and protecting their most vital IP assets, while also advising established companies responsible for advancing groundbreaking discoveries. We identify the areas in which intellectual property protection is most critical to achieving the company’s business objectives, determine the most effective methods of protection, and identify strategies to avoid issues with third-party patents. We have offices in Austin; Beijing; Boston; Brussels; Hong Kong; Los Angeles; New York; Palo Alto; San Diego; San Francisco; Seattle; Shanghai; Washington, D.C.; and Wilmington, DE.

Saul Ewing Arnstein & Lehr LLP: The 400-plus attorneys of Saul Ewing Arnstein & Lehr LLP are dedicated to providing client-centric counsel to businesses throughout the United States and internationally from our 17 offices stretching down the East Coast from Boston to Miami and extending into the Midwest by way of Chicago. We work with well-known corporations, exciting start-ups and an array of closely held and privately held companies, as well as institutions of higher education, nonprofits, and governmental entities. As a full-service law firm, we handle matters involving bankruptcy, business and finance, estates and trusts, litigation and real estate services. We also advise on intellectual property, immigration and foreign investment services. Energy, higher education, insurance and life sciences are among our core industries of focus.
WIGGIN AND DANA

Wiggin and Dana is a full-service law firm with 146 lawyers that represents clients throughout the country and abroad from our offices in Connecticut, New York, Philadelphia, Washington, DC, and Palm Beach. We provide a broad range of legal services to meet the needs of our diverse client base, which includes entrepreneurs and emerging growth companies, publicly traded companies, hospitals and other health care organizations, universities, real estate developers, financial institutions, museums, charitable organizations and individuals. Our primary mission is to provide our clients with the highest-quality legal services in an efficient, cost-effective and responsive manner to help them achieve their goals. Visit us at www.wiggin.com. We look forward to working with you.

ROYALTY PHARMA

Royalty Pharma Founded in 1996, Royalty Pharma is the industry leader in investing in marketed and late stage biopharmaceutical products. Central to our investment strategy is acquiring economic interests in leading pharmaceutical and biotechnology products, and holding these interests for the long term as part of a diversified portfolio. We invest broadly across product and therapeutic classes to capture the fundamentally attractive business model of the pharmaceutical industry, while limiting exposure to the concentrated product risk typical to many biopharmaceutical companies. The ability to provide competitive capital for highly innovative development-stage products across therapeutic areas, for companies of all sizes, makes Royalty Pharma the leading R&D partner for the biopharmaceutical industry. Royalty Pharma currently owns a diversified portfolio of royalty interests in several high-quality blockbuster biopharmaceutical products. Visit us at /www.royaltypharma.com.
Additional Sponsors

**Charles River**

*Industry-proven in successfully identifying and assessing novel therapies with over 320 patents and 75 preclinical drug development candidates delivered to our sponsors since 2001. Our comprehensive, integrated portfolio employs the latest technology and platforms to provide chemistry, biology, and pharmacology services.*

**Blue Ivy Ventures**

*Blue Ivy Ventures is a fund for Yale alumni interested in investing in ventures connected to fellow alums; it is private, for-profit, and not affiliated with or officially sanctioned by the University. Visit us at https://www.avgfunds.com/blue-ivy-ventures/*.

**Biohaven**

*Biohaven is a biopharmaceutical company innovating a portfolio of late-stage assets targeting neurologic diseases. Biohaven successfully combined experienced drug development with intellectual property licensed from leading pharma companies and academic institutions. For more information visit www.biohavenpharma.com*

**Canaan**

*Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and 190 exits to date, Canaan has invested in some of the world’s leading technology and healthcare companies.*

**Spring Mountain Capital**

*Spring Mountain Capital is a private investment management firm that focuses on alternative asset investing, offering a wide range of strategies to produce attractive risk-adjusted returns. Our solutions seek to meet clients’ needs and reflect the flexibility, adaptability and insight.*

**Bulldog Innovation Group**

*Bulldog Innovation Group is an early stage venture capital firm run entirely by Yale alumni with the mission to invest in the Yale entrepreneurial ecosystem. We are Yalies leveraging the strength of our networks to create BIG opportunities for entrepreneurs and investors alike.*
Additional Sponsors

Hamamatsu
Hamamatsu Corporation is the North American Subsidiary of Hamamatsu Photonics K.K. (Japan), a leading manufacturer of devices for the generation and measurement of infrared, visible, ultraviolet light, and x-rays. Our products are used throughout the world in scientific, industrial, and commercial applications.

Evotec
Is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. ‘RESEARCH NEVER STOPS’ Building innovative drug discovery alliances.

Murtha Cullina LLP
The Emerging Companies Practice Group at Murtha Cullina LLP offers legal counsel and strategic business planning to companies through all stages of their lifecycle: from the concept phase through development and growth periods, and through exit strategies, including sale events.

Yale School of Management
Yale School of Management – Program on Entrepreneurship. Established in 2014, the Program on Entrepreneurship at Yale School of Management is dedicated to the creation, preservation and dissemination of knowledge in the field of entrepreneurship and the education of entrepreneurial leaders for business and society.

Jubilant Biosystems
Jubilant Biosys has demonstrated expertise in multiple therapeutic areas including Oncology, Metabolic Disorders, Pain & Inflammation, and CNS. Our business model includes proprietary in-house innovation, and drug discovery services which are available for collaborative research, partnership and out-licensing.

Kleo Pharmaceuticals
Kleo Pharmaceuticals was formed to transform the pioneering research conducted by Dr. David Spiegel at Yale University into life-saving treatment options for patients. We are advancing the field of immunotherapy by developing small molecules that emulate biologics to fight specific disease causing cells.
Additional Sponsors

**IP Group, Inc.**

IP Group is an intellectual property commercialization company focused on evolving great ideas from its partner universities into world-changing businesses. We pioneered a unique approach to commercializing these ideas by providing access to capital, scientific insight and the supporting infrastructure.

**Ernst & Young**

EY is a global leader in assurance, tax, transaction and advisory services. Our Global Life Sciences Sector brings together a worldwide network of 15,000 sector-focused professionals to anticipate trends, identify their implications and help our clients create competitive advantage.

**Atlas Venture**

Atlas Venture is a leading biotech venture capital firm working side by side with exceptional scientists and entrepreneurs to build biotech startups that translate high impact science into medicines for patients. Visit us at www.atlasventure.com.

**Elm Street Ventures**

Elm Street Ventures is a seed and early stage venture fund based in New Haven, CT. Yale is our largest investor. >70% of investments have been in healthcare/life science companies. Visit us at www.elmvc.com.

**Yale New Haven Health**

Yale New Haven Health is a $4.4B health system with over 24,000 employees located primarily in Connecticut. YNHH enhances the lives of the people we serve by providing access to high value, patient-centered care in collaboration with those who share our values.
The team at OCR is skilled at identifying technologies with market potential, navigating the patent process, connecting Yale researchers with academic and industry partners, building management teams and introducing startups to funding sources.

Managing Director
Jon Soderstrom

Business Development Professionals
John W. Puziss - Director of Business Development
David A. Lewin - Senior Associate Director of Business Development
Hong Peng - Associate Director of Business Development
Christopher Unsworth - Associate Director of Business Development
Lolahon Kadiri - Business Development Associate
Valarie Truax - Business Development Associate
Richard L. Andersson - Senior Business Development Associate

New Ventures & Blavatnik Fund for Innovation at Yale
Bill Wiesler - Director of New Ventures, Director of Blavatnik Fund
James G. Boyle - Managing Director Yale Entrepreneurial Institute (YEI)

Entrepreneurs-in-Residence
John Dexheimer - Alexandra Mack
Brian Dixon - Bridget Martell
Colin Foster - Tim Riley
Susan Froshauer - Barry Schweitzer
Gene Griffin - Sapan Shah
Tom Jasinski - Michael Singer
Ron Lennox - Julie Vance

Operations Team
Timothy Opstrup - Director of Finance & Administration
Kevin Mahoney - Assistant Business Manager
Diane K. Harmon - Director of Intellectual Property Administration
Natasha G. Samuels - Intellectual Property Manager
Tina Muzzy - Intellectual Property Compliance Associate
DawnMarie Portoff - Senior Licensing Compliance Professional
Connie Rowley - Financial Assistant
Olga Rivera - Operations Coordinator
Ann Hollmann - Senior Administrative Assistant
About the Office of Cooperative Research

Fostering a culture of innovators, entrepreneurs and partners across Yale, and supporting the advancement of their innovations towards the benefit of society

Since its founding in 1982, the Yale Office of Cooperative Research (OCR) has built a significant portfolio of inventions and patents and has grown into an engine of regional economic development. Its mission is to facilitate the translation of research from Yale’s labs into products and services that benefit society. OCR is recognized as a leading force for catalyzing economic growth by identifying, counseling and nurturing early-stage technologies and guiding the transition into robust companies.

As we accomplish our mission, we seek to:

• Enhance the research reputation of the university
• Assist Yale in recruiting and retaining the best faculty, staff, and students
• Catalyze local economic development

ocr.yale.edu